[
  {
    "date": "2024-02-28",
    "symbol": "BZYR",
    "period": "FY",
    "documenttype": "10-K",
    "documentannualreport": "true",
    "documentperiodenddate": "2024-02-29",
    "documenttransitionreport": "false",
    "entityfilenumber": "000-23425",
    "entityregistrantname": "BURZYNSKI RESEARCH INSTITUTE INC",
    "entityincorporationstatecountrycode": "DE",
    "entitytaxidentificationnumber": "76-0136810",
    "entityaddressaddressline1": "9432 Katy Freeway",
    "entityaddresscityortown": "Houston",
    "entityaddressstateorprovince": "TX",
    "entityaddresspostalzipcode": 77055,
    "cityareacode": 713,
    "localphonenumber": "335-5697",
    "tradingsymbol": "BZYR",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "documentfinstmterrorcorrectionflag": "false",
    "entityshellcompany": "false",
    "entitycentralindexkey": 724445,
    "currentfiscalyearenddate": "--02-29",
    "documentfiscalyearfocus": 2024,
    "documentfiscalperiodfocus": "FY",
    "amendmentflag": "false",
    "security12gtitle": "Common Stock, $.001 par value",
    "entityvoluntaryfilers": "No",
    "entitywellknownseasonedissuer": "No",
    "auditorname": "Pannell Kerr Forster",
    "auditorfirmid": 342,
    "auditorlocation": "Houston, Texas",
    "cashandcashequivalentsatcarryingvalue": 1310,
    "prepaidexpensecurrent": 1000,
    "assetscurrent": 2310,
    "assets": 2310,
    "accountspayablecurrent": 9010,
    "accruedliabilitiescurrent": 18423,
    "liabilities": 27433,
    "commonstockvalue": 131449,
    "additionalpaidincapitalcommonstock": 127933634,
    "retainedearningsaccumulateddeficit": -128090206,
    "stockholdersequity": -25123,
    "liabilitiesandstockholdersequity": 2310,
    "commonstockparorstatedvaluepershare": 0.001,
    "commonstocksharesauthorized": 200000000,
    "commonstocksharesissued": 131448444,
    "commonstocksharesoutstanding": 131448444,
    "researchanddevelopmentexpense": 864999,
    "generalandadministrativeexpense": 470432,
    "operatingexpenses": 1335431,
    "operatingincomeloss": -1335431,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -1335431,
    "netincomeloss": -1335431,
    "earningspersharebasic": -0.01,
    "earningspersharediluted": -0.01,
    "weightedaveragenumberofsharesoutstandingbasic": 131448444,
    "weightedaveragenumberofdilutedsharesoutstanding": 131448444,
    "sharesoutstanding": 131448444,
    "adjustmentstoadditionalpaidincapitalcashcontributed": 524156,
    "adjustmentstoadditionalpaidincapitalother": 799879,
    "profitloss": -1335431,
    "clinicaltrialexpensespaid": 799879,
    "increasedecreaseinaccountspayable": -3560,
    "increasedecreaseinaccruedliabilities": 15332,
    "netcashprovidedbyusedinoperatingactivities": -523780,
    "proceedsfromcontributedcapital": 524156,
    "netcashprovidedbyusedinfinancingactivities": 524156,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseexcludingexchangerateeffect": 376,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 1310,
    "ownershipinterestpercentageheldbycompanypresidentandchairmanofboard": 0.81,
    "propertyplantandequipmentusefullife": "P5Y",
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 600000,
    "relatedpartytransactionnumberofothercountriesinwhichpatentofficesandpatentofficersissuedpatents": 34,
    "relatedpartytransactionnumberofpatentsowned": 8,
    "relatedpartytransactionnumberofparties": 2,
    "relatedpartytransactionnetproceedsfromstockofferingthatreducepaymentobligation": 1000000,
    "relatedpartytransactionrenewableperiod": "P1Y",
    "relatedpartytransactionnoticeperiodfornonrenewalpriortoexpirationoftermofagreement": "P30D",
    "relatedpartytransactionownershippercentageforautomaticterminationofagreement": 0.5,
    "relatedpartytransactionroyaltyinterestaspercentageofgrossincome": 0.1,
    "relatedpartytransactionnumberofpatientstobetreatedwithantineoplastonproductsproductionwithoutpayinganyfeesoptionone": 1000,
    "relatedpartytransactionnumberofpatientstobetreatedwithantineoplastonproductspurchaseatspecifiedpriceoptiontwo": 1000,
    "relatedpartytransactionnumberofpatientstobetreatedwithantineoplastonproductsinoptiontwopercentageaddedtoproductioncost": 0.1,
    "selffundedemployeebenefitplanpretaxpremiumpermonth": 1465,
    "lesseeoperatingleasetermofcontract": "P1Y",
    "operatingleaseexpense": 71500,
    "operatingleasecost": 295456,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": 280441,
    "incometaxreconciliationdeductions": 280441,
    "incometaxreconciliationnondeductibleexpense": -2394,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": 2394,
    "deferredtaxassetsoperatinglosscarryforwards": 121628,
    "deferredtaxassetstaxcreditcarryforwardsalternativeminimumtax": 42603,
    "deferredtaxassetsgross": 164231,
    "deferredtaxassetsvaluationallowance": 164231,
    "operatinglosscarryforwards": 44638,
    "percentageoffuturetaxableincomenetoperatinglosscarryforwards": 0.8,
    "percentageonnetoperatinglosscarryforwardslimitoftaxableincomeundercoronavirusaidreliefandeconomicsecurityact": 0.8,
    "taxcutsandjobsactof2017netoperatinglosscarryforwards": 473902,
    "netoperatinglosscarryforwardindefinitely": 105277,
    "alternativeminimumtaxcreditcarryforwards": 42603,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofplans": 1,
    "supplycommitmentnumberofpatientswhocanbetreatedperyearwithcurrentproductioncapacityofantineoplastonproducts": 1000,
    "valueofsuppliespurchased": 21,
    "rule10b51arradoptedflag": "false",
    "nonrule10b51arradoptedflag": "false",
    "rule10b51arrtrmntdflag": "false",
    "nonrule10b51arrtrmntdflag": "false"
  },
  {
    "date": "2014-02-27",
    "symbol": "BZYR",
    "period": "FY",
    "ownershipinterestpercentageheldbycompanypresidentandchairmanofboard": 0.809,
    "workingcapitaldeficit": 153000,
    "retainedearningsaccumulateddeficit": -112371664,
    "netincomelossavailabletocommonstockholdersbasic": -4271785,
    "estimatedpercentofrelatedpartiespatientsadmittedandtreatedunderclinicaltrialprograms": 0.1,
    "propertyplantandequipmentusefullife": "P10Y",
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 1600000,
    "operatinglosscarryforwards": 76642,
    "alternativeminimumtaxcreditcarryforwards": 42603,
    "operatingleaseterm": "P4Y",
    "operatingleasesrentexpensenet": 90752,
    "operatingleasesfutureminimumpaymentsduecurrent": 37440,
    "operatingleasesfutureminimumpaymentsdueintwoyears": 34562,
    "operatingleasesfutureminimumpaymentsdueinthreeyears": 20172,
    "operatingleasesfutureminimumpaymentsdue": 92174,
    "leaseandrentalexpense": 269401,
    "relatedpartytransactionnumberofpatientstobetreatedwithantineoplastonproductsproductionwithoutpayinganyfeesoptionone": 1000,
    "relatedpartytransactionnumberofpatientstobetreatedwithantineoplastonproductspurchaseatspecifiedpriceoptiontwo": 1000,
    "relatedpartytransactionnumberofpatientstobetreatedwithantineoplastonproductsinoptiontwopercentageaddedtoproductioncost": 0.1,
    "supplycommitmentnumberofpatientsforwhosetreatmententityproducedantineoplastonproducts": 16,
    "supplycommitmentnumberofpatientswhocanbetreatedperyearwithcurrentproductioncapacityofantineoplastonproducts": 1500,
    "relatedpartytransactionnumberofothercountriesinwhichpatentofficesandpatentofficersissuedpatents": 34,
    "relatedpartytransactionnumberofpatentsowned": 1,
    "relatedpartytransactionnumberofinitialpatents": 5,
    "relatedpartytransactionnumberofparties": 2,
    "relatedpartytransactionnetproceedsfromstockofferingthatreducepaymentobligation": 1000000,
    "relatedpartytransactionrenewableperiod": "P1Y",
    "relatedpartytransactionnoticeperiodfornonrenewalpriortoexpirationoftermofagreement": "P30D",
    "relatedpartytransactionownershippercentageforautomaticterminationofagreement": 0.5,
    "relatedpartytransactionroyaltyinterestaspercentageofgrossincome": 0.1,
    "adjustmentstoadditionalpaidincapitalcashcontributed": 437400,
    "adjustmentstoadditionalpaidincapitalclinicaltrialexpenses": -3768425,
    "selffundedemployeebenefitplanpretaxpremiumpermonth": 525,
    "selffundedemployeebenefitplannumberofinsurancecoverageplans": 2,
    "selffundedemployeebenefitplandeductibleamountunderinsurancecoverageplan": 600,
    "selffundedemployeebenefitplanlifetimebenefitsperparticipantunderinsurancecoverageplan": 2000000,
    "selffundedemployeebenefitplanbenefitspayableperperson": 35000,
    "selffundedemployeebenefitplancost": 363031,
    "definedcontributionplanemployerdiscretionarycontributionamount": 699,
    "propertyplantandequipmentgross": 22415,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 20363,
    "propertyplantandequipmentnet": 2052,
    "depreciationdepletionandamortization": 684,
    "concentrationriskpercentage1": 0.91,
    "numberofsuppliers": 1,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.34,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": -1452407,
    "incometaxreconciliationdeductions": -1452407,
    "incometaxreconciliationotheradjustments": -22426,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": 22426,
    "deferredtaxassetsoperatinglosscarryforwards": 237916,
    "deferredtaxassetspropertyplantandequipment": -591,
    "deferredtaxassetstaxdeferredexpensereservesandaccrualsaccruedliabilities": 2268,
    "deferredtaxassetstaxcreditcarryforwardsalternativeminimumtax": 42603,
    "deferredtaxassetsgross": 282196,
    "deferredtaxassetsvaluationallowance": 282196,
    "researchanddevelopmentexpense": 3963418,
    "generalandadministrativeexpense": 307683,
    "operatingexpenses": 4271785,
    "operatingincomeloss": -4271785,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -4271785,
    "earningspersharebasicanddiluted": -0.03,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 131448444,
    "clinicaltrialexpensespaid": 3768425,
    "increasedecreaseinaccountspayable": 66819,
    "increasedecreaseinaccruedliabilities": -2506,
    "netcashprovidedbyusedinoperatingactivitiescontinuingoperations": -438363,
    "proceedsfromcontributedcapital": 437400,
    "netcashprovidedbyusedinfinancingactivitiescontinuingoperations": 437400,
    "netcashprovidedbyusedincontinuingoperations": -963,
    "cashandcashequivalentsatcarryingvalue": 229,
    "commonstockparorstatedvaluepershare": 0.001,
    "commonstocksharesauthorized": 200000000,
    "commonstocksharesissued": 131448444,
    "commonstocksharesoutstanding": 131448444,
    "entityregistrantname": "BURZYNSKI RESEARCH INSTITUTE INC",
    "entitycentralindexkey": 724445,
    "documenttype": "10-K",
    "documentperiodenddate": "2014-02-28",
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--02-28",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Smaller Reporting Company",
    "documentfiscalyearfocus": 2014,
    "documentfiscalperiodfocus": "FY",
    "assetscurrent": 229,
    "assets": 2281,
    "accountspayablecurrent": 114320,
    "accruedliabilitiescurrent": 38583,
    "liabilitiescurrent": 152903,
    "liabilities": 152903,
    "commonstockvalue": 131449,
    "additionalpaidincapitalcommonstock": 112089593,
    "stockholdersequity": -150622,
    "liabilitiesandstockholdersequity": 2281,
    "sharesoutstanding": 131448444
  },
  {
    "date": "2013-02-27",
    "symbol": "BZYR",
    "period": "FY",
    "ownershipinterestpercentageheldbycompanypresidentandchairmanofboard": 0.809,
    "workingcapitaldeficit": 87000,
    "retainedearningsaccumulateddeficit": -108099879,
    "netincomelossavailabletocommonstockholdersbasic": -6498806,
    "estimatedpercentofrelatedpartiespatientsadmittedandtreatedunderclinicaltrialprograms": 0.1,
    "propertyplantandequipmentusefullife": "P10Y",
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 1600000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.34,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": -2209594,
    "incometaxreconciliationdeductions": -2209594,
    "incometaxreconciliationotheradjustments": -51160,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": 51160,
    "deferredtaxassetsoperatinglosscarryforwards": 211858,
    "deferredtaxassetspropertyplantandequipment": -616,
    "deferredtaxassetstaxdeferredexpensereservesandaccrualsaccruedliabilities": 5925,
    "deferredtaxassetstaxcreditcarryforwardsalternativeminimumtax": 42603,
    "deferredtaxassetsgross": 259770,
    "deferredtaxassetsvaluationallowance": 259770,
    "concentrationriskpercentage1": 0.87,
    "numberofsuppliers": 1,
    "relatedpartytransactionnumberofothercountriesinwhichpatentofficesandpatentofficersissuedpatents": 34,
    "relatedpartytransactionnumberofpatentsowned": 1,
    "relatedpartytransactionnumberofinitialpatents": 5,
    "relatedpartytransactionnumberofparties": 2,
    "relatedpartytransactionnetproceedsfromstockofferingthatreducepaymentobligation": 1000000,
    "relatedpartytransactionrenewableperiod": "P1Y",
    "relatedpartytransactionnoticeperiodfornonrenewalpriortoexpirationoftermofagreement": "P30D",
    "relatedpartytransactionownershippercentageforautomaticterminationofagreement": 0.5,
    "relatedpartytransactionroyaltyinterestaspercentageofgrossincome": 0.1,
    "relatedpartytransactionnumberofpatientstobetreatedwithantineoplastonproductsproductionwithoutpayinganyfeesoptionone": 1000,
    "relatedpartytransactionnumberofpatientstobetreatedwithantineoplastonproductspurchaseatspecifiedpriceoptiontwo": 1000,
    "relatedpartytransactionnumberofpatientstobetreatedwithantineoplastonproductsinoptiontwopercentageaddedtoproductioncost": 0.1,
    "adjustmentstoadditionalpaidincapitalcashcontributed": 655182,
    "adjustmentstoadditionalpaidincapitalclinicaltrialexpenses": 5640314,
    "selffundedemployeebenefitplanpretaxpremiumpermonth": 525,
    "selffundedemployeebenefitplannumberofinsurancecoverageplans": 2,
    "selffundedemployeebenefitplandeductibleamountunderinsurancecoverageplan": 600,
    "selffundedemployeebenefitplanlifetimebenefitsperparticipantunderinsurancecoverageplan": 2000000,
    "selffundedemployeebenefitplanbenefitspayableperperson": 25000,
    "selffundedemployeebenefitplancost": 539492,
    "definedcontributionplanemployerdiscretionarycontributionamount": 507,
    "supplycommitmentnumberofpatientsforwhosetreatmententityproducedantineoplastonproducts": 59,
    "supplycommitmentnumberofpatientswhocanbetreatedperyearwithcurrentproductioncapacityofantineoplastonproducts": 1500,
    "propertyplantandequipmentgross": 22415,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 19679,
    "propertyplantandequipmentnet": 2736,
    "depreciationdepletionandamortization": 683,
    "operatingleaseterm": "P4Y",
    "operatingleasesrentexpensenet": 151695,
    "operatingleasesfutureminimumpaymentsduecurrent": 37440,
    "operatingleasesfutureminimumpaymentsdueintwoyears": 37440,
    "operatingleasesfutureminimumpaymentsdueinthreeyears": 34562,
    "operatingleasesfutureminimumpaymentsdueinfouryears": 20172,
    "operatingleasesfutureminimumpaymentsdue": 129614,
    "leaseandrentalexpense": 256198,
    "operatinglosscarryforwards": 31868,
    "alternativeminimumtaxcreditcarryforwards": 42603,
    "cashandcashequivalentsatcarryingvalue": 1192,
    "assetscurrent": 1192,
    "assets": 3928,
    "accountspayablecurrent": 47501,
    "accruedliabilitiescurrent": 41089,
    "liabilitiescurrent": 88590,
    "liabilities": 88590,
    "commonstockvalue": 131449,
    "additionalpaidincapitalcommonstock": 107883768,
    "stockholdersequity": -84662,
    "liabilitiesandstockholdersequity": 3928,
    "entityregistrantname": "BURZYNSKI RESEARCH INSTITUTE INC",
    "entitycentralindexkey": 724445,
    "documenttype": "10-K",
    "documentperiodenddate": "2013-02-28",
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--02-28",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Smaller Reporting Company",
    "documentfiscalyearfocus": 2013,
    "documentfiscalperiodfocus": "FY",
    "commonstockparorstatedvaluepershare": 0.001,
    "commonstocksharesauthorized": 200000000,
    "commonstocksharesissued": 131448444,
    "commonstocksharesoutstanding": 131448444,
    "clinicaltrialexpensespaid": 5640314,
    "issuanceofstockandwarrantsforservicesorclaims": 159896,
    "increasedecreaseinaccountspayable": 35236,
    "increasedecreaseinaccruedliabilities": -8610,
    "netcashprovidedbyusedinoperatingactivitiescontinuingoperations": -671287,
    "proceedsfromcontributedcapital": 655182,
    "netcashprovidedbyusedinfinancingactivitiescontinuingoperations": 655182,
    "netcashprovidedbyusedincontinuingoperations": -16105,
    "researchanddevelopmentexpense": 6047676,
    "generalandadministrativeexpense": 450697,
    "operatingexpenses": 6499056,
    "operatingincomeloss": -6499056,
    "othernonoperatingincome": 250,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -6498806,
    "earningspersharebasicanddiluted": -0.05,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 131448444,
    "sharesoutstanding": 131448444
  },
  {
    "date": "2012-02-28",
    "symbol": "BZYR",
    "period": "FY",
    "entityregistrantname": "BURZYNSKI RESEARCH INSTITUTE INC",
    "entitycentralindexkey": 724445,
    "documenttype": "10-K",
    "documentperiodenddate": "2012-02-29",
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--02-29",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Smaller Reporting Company",
    "documentfiscalyearfocus": 2012,
    "documentfiscalperiodfocus": "FY",
    "cashandcashequivalentsatcarryingvalue": 17297,
    "assetscurrent": 17297,
    "propertyplantandequipmentnet": 3419,
    "assets": 20716,
    "accountspayablecurrent": 12265,
    "accruedliabilitiescurrent": 49699,
    "liabilitiescurrent": 61964,
    "liabilities": 61964,
    "commonstockvalue": 131449,
    "additionalpaidincapitalcommonstock": 101428376,
    "retainedearningsaccumulateddeficit": -101601073,
    "stockholdersequity": -101601073,
    "liabilitiesandstockholdersequity": 20716,
    "commonstockparorstatedvaluepershare": 0.001,
    "commonstocksharesauthorized": 200000000,
    "commonstocksharesissued": 131448444,
    "commonstocksharesoutstanding": 131448444,
    "researchanddevelopmentexpense": 6925519,
    "generalandadministrativeexpense": 231442,
    "depreciationdepletionandamortization": 701,
    "operatingexpenses": 7157662,
    "operatingincomeloss": -7157662,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -7157662,
    "netincomelossavailabletocommonstockholdersbasic": -7157662,
    "earningspersharebasicanddiluted": -0.05,
    "weightedaveragenumberofsharesoutstandingbasic": 131448444,
    "weightedaveragenumberofdilutedsharesoutstanding": 131443156,
    "sharesoutstanding": 131448444,
    "adjustmentstoadditionalpaidincapitalcashcontributed": 503885,
    "adjustmentstoadditionalpaidincapitalclinicaltrialexpenses": -6663784,
    "clinicaltrialexpensespaid": 6663784,
    "increasedecreaseinaccountspayable": -26958,
    "increasedecreaseinaccruedliabilities": 16071,
    "netcashprovidedbyusedinoperatingactivitiescontinuingoperations": -504064,
    "proceedsfromcontributedcapital": 503885,
    "netcashprovidedbyusedinfinancingactivitiescontinuingoperations": 503885,
    "netcashprovidedbyusedincontinuingoperations": -179
  }
]